Virtual research support pilot
Active Awarded Last action
- Contract number
- 75N91022F00023
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $8,703,603
Award facts
- Contract value 100% obligated
- $8,703,603.00 Current and potential, with all options
- Completion date 82% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$513,380 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Original award | $9,216,983 |
About this award
The National Cancer Institute awarded Leidos Biomedical Research Inc., a Federally Funded Research and Development Center (FFRDC) contractor, a delivery order contract valued at $8.7 million for the Virtual Research Support Pilot initiative supporting the President's Department of Government Efficiency Cost Efficiency Initiative as of March 19, 2025. This cost-plus-fixed-fee contract, awarded on September 15, 2022, with an ultimate completion date of September 14, 2027, carries no set-aside designation and will be performed at the company's Frederick, Maryland location. Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc., a major global technology and engineering solutions provider headquartered in Reston, Virginia.
The award supports the National Cancer Institute's broader mission of advancing cancer research through comprehensive biomedical research and facilities support services. Leidos Biomedical Research Inc.'s FFRDC role positions it to deliver critical research, development, and operational support across multiple scientific domains, including medical research infrastructure, clinical trials support, and advanced technological solutions. The contractor's extensive portfolio includes prior work on gene therapy development, infectious disease research, clinical trial coordination, therapeutic agent manufacturing, and specialized laboratory testing—capabilities directly aligned with supporting federal scientific research and development efforts across the National Institutes of Health enterprise.
Quick answers
Who was awarded contract 75N91022F00023?
75N91022F00023 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2022.
How much is contract 75N91022F00023 worth?
The government has obligated $8,703,603 on 75N91022F00023.
Is contract 75N91022F00023 an order under another contract?
Yes. 75N91022F00023 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00023 competed?
The extent of competition for 75N91022F00023 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award